Holen Sie sich die Stockscreener-App
2.37
5.80%
0.13
Handel nachbörslich:
2.34
-0.03
-1.27%
Schlusskurs vom Vortag:
$2.24
Offen:
$2.25
24-Stunden-Volumen:
2.50M
Relative Volume:
0.20
Marktkapitalisierung:
$300.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.47M
KGV:
-4.1579
EPS:
-0.57
Netto-Cashflow:
$-124.27M
1W Leistung:
-17.71%
1M Leistung:
-47.80%
6M Leistung:
+48.12%
1J Leistung:
+4.41%
1-Tages-Spanne:
$2.195
$2.46
1-Wochen-Bereich:
$2.16
$2.98
52-Wochen-Spanne:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Vergleichen Sie PROK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.37 | 300.86M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook - TipRanks
ProKidney Corp. Reports Q2 2025 Financial Results - TipRanks
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewswire
ProKidney reports Q2 EPS (13c), consensus (14c) - TipRanks
ProKidney's Breakthrough: FDA Backs Fast-Track Path as Kidney Treatment Shows Strong Phase 2 Results - Stock Titan
ProKidney (PROK.O) Sees Sharp Intraday Drop — But No Fundamental Catalyst — What’s Really Behind the Move? - AInvest
ProKidney Shares Double on Strong Phase 2 Data for Kidney Disease Therapy - MSN
ProKidney And 2 Other Penny Stocks To Watch Closely - Yahoo Finance
ProKidney PROK 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth and Analyst Upgrades - AInvest
What institutional investors are buying ProKidney Corp. stockGet timely alerts on top-performing stocks - Jammu Links News
Meet the Biotech Stock That Rocketed 775% Higher - MSN
What is the dividend policy of ProKidney Corp. stockFree Technical Analysis Support - Jammu Links News
Is ProKidney Corp. stock overvalued or undervaluedInvest confidently with market-leading analysis - Jammu Links News
What catalysts could drive ProKidney Corp. stock higher in 2025Free Stock Market Return Analysis - Jammu Links News
What makes ProKidney Corp. stock price move sharplyGet daily updates on top-performing stocks - Jammu Links News
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
What are the technical indicators suggesting about ProKidney Corp.Get exclusive access to premium stock research - Jammu Links News
What analysts say about ProKidney Corp. stockAchieve triple-digit returns with smart investing - Jammu Links News
What are analysts’ price targets for ProKidney Corp. in the next 12 monthsConsistent high-yield stocks - Jammu Links News
Is ProKidney Corp. a growth stock or a value stockHigh-margin investment plays - Jammu Links News
Is it the right time to buy ProKidney Corp. stockAchieve consistent profits with expert strategies - Jammu Links News
How volatile is ProKidney Corp. stock compared to the marketRapid growth opportunities - Jammu Links News
What are ProKidney Corp. company’s key revenue driversCapitalize on emerging market trends - Jammu Links News
When is ProKidney Corp. stock expected to show significant growthDiscover breakthrough trading strategies - Jammu Links News
How does ProKidney Corp. generate profit in a changing economyUnlock rapid growth potential in your portfolio - Jammu Links News
How does ProKidney Corp. compare to its industry peersHigh-octane investment opportunities await - Jammu Links News
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - 富途牛牛
What is ProKidney Corp. company’s growth strategyAdvanced Screener Planner For 2025 - Jammu Links News
Can ProKidney Corp. Regain Lost Ground This QuarterStep-by-Step Stock Investment Guide Gains Popularity - metal.it
How strong is ProKidney Corp. company’s balance sheetAdvanced Screener Planner For 2025 - jammulinksnews.com
How ProKidney Corp. stock performs during market volatilityWeekly Stock Opportunity Radar Scanner Activated - beatles.ru
Published on: 2025-07-30 17:58:00 - beatles.ru
Published on: 2025-07-29 09:29:22 - metal.it
Wyckoff Accumulation Phase Possible in ProKidney Corp.Buy Low Sell High Stock Watch Strategy in Focus - metal.it
Does ProKidney Corp. stock perform well during market downturnsBuild wealth with reliable stock picks - Jammu Links News
Key External Factors That Drive ProKidney Corp. Stock Price MovementsFree Stock Market Group - metal.it
ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed - The Rhino Times of Greensboro -
Is ProKidney Corp. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia
Published on: 2025-07-25 13:32:55 - PrintWeekIndia
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment - TipRanks
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):